Docstoc

Our Path Forward

Document Sample
Our Path Forward Powered By Docstoc
					       Our Path Forward
                Joe Feczko
Senior Vice President & Chief Medical Officer
Forward-Looking Statements


  Our discussions at this meeting will include forward-looking statements.
  Actual results could differ materially from those projected in the forward-
  looking statements. The factors that could cause actual results to differ
  are discussed in Pfizer’s 2007 Annual Report on Form 10-K and in our
  reports on Form 10-Q and Form 8-K.

  These reports are available on our website at www.pfizer.com in the
  "Investors—SEC Filings" section.
The Forces at Work in Healthcare Today

                                                               ty in
                             in
                        ances gy                    Aging Socie orld
                    Adv                                    ed W
         Pr ofound Technolo                         Develop
                   nd                  Risi
        Sci ence a                         ng M
                                         in D iddle
                                             eve
                    Info                    Reg   lopi Class
                   Exp rmatio                   ions ng
                       l       n
                   New osion &
                         Med
                            ia
               m                                          Health US
        m eris                                                  ca
    n su                                                   Conso re Plans
  Co                                                             lidatin
                                                                        g
                    Shift in Who
                                 “   Owns” the D
                                                 ata

                   Transp
                          a
                   Cost an rency of                      Affordability
                          d Quali
                                  ty
5 Key Strategies

                             Refocus
                          and Optimize
                           the Patent-
                            protected
                            Portfolio
             Instill a                     Find New
            Culture of                   Opportunities
         Innovation and                       for
           Continuous                     Established
          Improvement                      Products




                Invest in             Grow in
              Complementary          Emerging
               Businesses             Markets
5 Key Strategies

                             Refocus
                          and Optimize
                           the Patent-
                            protected
                            Portfolio
             Instill a                     Find New
            Culture of                   Opportunities
         Innovation and                       for
           Continuous                     Established
          Improvement                      Products




                Invest in             Grow in
              Complementary          Emerging
               Businesses             Markets
Disease Area Priorities

                        Invest to Win

          First or        High Market           High
        Best in Class       Growth           Unmet Need




                                  Oncology
                                  Pain
                                  Immunology / Inflammation
                                  Diabetes / Obesity
                                  Alzheimer’s Disease
                                  Schizophrenia
Today’s Phase 3 Portfolio



               axitinib – Pancreatic Cancer       PD-332334 – GAD

               tremelimumab – Melanoma            S,S-reboxetine – Fibromyalgia
   NMEs
               apixaban – VTE Prevention          Zithromax/chloroquine – Malaria

               CP-945598 – Obesity




    New
 Indications   apixaban –
               Atrial Fibrillation            /
Projected 15–20 Phase 3 Starts 2008–2009



               PF-3187207         PF-885706 – GERD          PF-868554    PF-734200
               – Glaucoma                                   – HCV        – Diabetes
                                  PF-299804 – Cancer
               CP-751871                                    PF-4194471   PF-4522625
               – Lung Cancer      PH-797804 – RA            – HIV        – Seasonal Flu
   NMEs        PF-4383119         IV sulopenem/Oral         CP-690550    UK-453061
               – OA Pain          sulopenem pro-drug        – RA         – HIV
                                  – Bacterial Infections
               PD-200390
               – Insomnia


               apixaban – VTE        PF-4383119
               treatment & ACS       – Chronic Pain
               axitinib – RCC &      tremelimumab – CRC
    New        Lung
                                     S,S-reboxetine – DPN
 Indications
Potential New Indications Expected
To Drive Value




                                                       Colorectal




                                      es
                                    nu
                                  ve
                                             Non Small Cell Lung




                                Re
                                        Hepatocellular Carcinoma


                                                          Breast



            Renal Cell Carcinoma & Gastrointestinal Stromal Tumor


                                 Time
Projected 15–20 Submissions 2010–2012


               axitinib – Pancreatic Cancer   Zithromax/chloroquine       PF-734200 – Diabetes
                                              – Malaria
               S,S-reboxetine                                             PD-200390 – Insomnia
               – Fibromyalgia                 PF-299804 – Cancer
                                                                          CP-751871
               CP-945598 – Obesity            PF-885706 – GERD            – 3rd Line NSCLC
   NMEs        PD-332334 – GAD                PF-4522625 – Seasonal Flu   PF-4383119 – OA Pain
               IV sulopenem / Oral            PH-797804 – RA              CP-690550 – RA
               sulopenem pro-drug
               – Bacterial Infections         PF-868554 – HCV

               UK-453061 – HIV                PF-4194471 – HIV



               axitinib – 1st Line            S,S-reboxetine – DPN
                            nd
               NSCLC & 2         Line RCC     CP-690550 – Psoriasis
               apixaban – VTE                 PF-4383119
    New        Treatment, AF & Acute
               Coronary Syndrome
                                              – Chronic Pain

 Indications
                                                                                 /
Steps to Improve Execution




 Focus Resources
     on Best        Identify Winners Early
  Opportunities



                    Improve Clinical Trial Design to Increase
 Improve Clinical   Probability of a Positive Result
  Trial Execution
                    Improve Cycle Times
Optimizing the Patent-Protected Portfolio
Lipitor: Maintaining Leadership Under
Intense Competition

   Lipitor 2007 Worldwide Sales                      2008 Focus


                                       U.S.
                                              Reinforce differentiation with
     Japan/Asia
                                      $7.8B
                                              compelling body of clinical
       $1.5B
       (+7%)                          (-6%)   and outcomes evidence

  Canada/                                     Drive activities targeted at
    Latin                                     new and continuing patients
  America/
   Africa/
 Middle East                                  Maintain and leverage
    $1.3B                                     access
    (+9%)
                                              Communicate data from
                  Europe
                                              Lipitor’s strong clinical
                   $3.0B
                   (-3%)                      program



                    Source: IMS MAT 4Q2007
Global Lyrica Forward Plan:
Differentiate, Grow and Expand

        2007                                       2008 +
  Core Indications                       Strengthen Core and Expand


                                                              Restless
                                                               Legs
                                                             Syndrome
                   Epilepsy
 Neuropathic
    Pain                                       Neuropathic
               GAD                                Pain
                                                                  Post Op
                              Epilepsy                             Pain
           Fibro

                                                             Fibromyalgia

                                                   GAD
Celebrex:
Preserve Today & Set the Stage for Growth



               Strengthen
                                 Repair the Patient-           Optimize
Near-Term   Understanding of
                                 Physician Dialogue            Execution
            Efficacy & Safety




Mid-Term                  Completion of Large Safety Studies
                              (CONDOR, PRECISION)
Chantix: For Smokers Motivated to Quit

                         45M Smokers                      25M Smokers
                          in the U.S.                    Motivated to Quit


                                      Control
                   Immature
                                      Takers
                    Quitters
                                        26%
                     25%
                                       11.7M
Desire to Quit




                                                    Chantix
                                                     Target

                                     MD/Rx-
                     Defiant        Dependent
                    Smokers          Quitters
                      20%              29%
                                      13.0M


                 Openness to Medical Intervention
Sutent: The Bedrock of
Our Oncology Portfolio

             U.S.                                     Potential New Indications
  mRCC Patient Share – 1st Line                        Expected to Drive Value
70%


60%

                                                                                  CRC
50%                                       53%




                                                                    es
                                                                  nu
40%




                                                                ve
                                                                             NSCLC




                                                              Re
30%                                                                               HCC
                                      Nexavar, 25%
20%                                                                                BC

                                      cytokine, 11%
10%
                                      Torisel, 7%                         RCC / GIST
                                      Other, 5%
0%
      J F M A M J   J A S O N D
                2007                                            Time


                       Source: ImpactRx
5 Key Strategies

                             Refocus
                          and Optimize
                           the Patent-
                            protected
                            Portfolio
             Instill a                     Find New
            Culture of                   Opportunities
         Innovation and                       for
           Continuous                     Established
          Improvement                      Products




                Invest in             Grow in
              Complementary          Emerging
               Businesses             Markets
The Opportunity


               Global Pharmaceutical Sales ($ billions USD)


                                              $898
                                                                      CAGR


                   $576                                                         “Established”
                                             $523                      11%        Market Is:
 Established                                                                     Big
 Products
 (Near-Post
                  $271                                                           Fast growing
 LOE)                                                                            Profitable
 Innovative
                                             $375                          4%
 Products         $305
 (Pre-LOE)

                  2006                       2012


                   * Excludes Africa/Middle East market.
                   Source: Datamonitor; EvaluatePharma; analyst reports.
The Market Is Not Homogenous,
Three Distinct Market Segments




                                     Branded Emerging Markets
                                     Branded Traditional Markets
                                     IP-Driven Markets
           Source: Datamonitor; EvaluatePharma; analyst reports.
Our Competitive Advantage =
Value Creation

                                         Leverage
 Strengths & Capabilities               Our Product
                                         Portfolio
  Strong brand recognition
     Track record of proven efficacy
     and safety                                   Become a
                                                World Leader
  Strong book of business today in               in Product
  established products                        Enhancements and
     Current portfolio about 4%                 Reformulation
     of market
  Broad and deep commercial
  infrastructure around the world
                                                   Pursue
  Excellence in Pharmaceutical                 Opportunities in
  Sciences                                     “Niche” Markets
     Enhancing our value proposition
  State-of-the-art manufacturing
  processes and technologies            Intensify Late
                                       Stage Lifecycle
                                           Planning
Our Goal – Outpace Market Growth

           Increase
          Emphasis on
    1     Our Existing
           Portfolio

                    Broaden the
                    Geographic
            2       Reach of Our
                     Offerings

                                 Develop
                              Partnerships
                         3    to Accelerate
                                Our Pace
5 Key Strategies

                             Refocus
                          and Optimize
                           the Patent-
                            protected
                            Portfolio
             Instill a                     Find New
            Culture of                   Opportunities
         Innovation and                       for
           Continuous                     Established
          Improvement                      Products




                Invest in             Grow in
              Complementary          Emerging
               Businesses             Markets
Right Geographies

                                  #2 Europe
                                    $13.3B
                                  7.0% Share


              #1 U.S.                  #4 Africa/                #1 Japan
               $25.5B                 Middle East    #1 Asia
                                                                    $3.7B
             9.2% Share                   $0.4B        $2.6B     6.4% Share
                                       5.8% Share   5.5% Share


                    #1 Latin
                    America
                      $1.4B
                   6.1% Share




     The Powerful Forces of Globalization Play to Our Strength


             Source: IMS MAT 4Q2007
Right Products

    New          In-Line                    Established




                                                                     (glipizide) Extended Release Tablets




                           Dynastat                          ®

                                                             IV/IM
                             (parecoxib sidico injectable)
The Emerging Asian Markets Opportunity


     Today                         2012 Projection                                    2017 Projection

                                                                                                               7–9%
                                                             6%
             4%




     $47B                               $79B                                                 $111B



                                      Market              Pfizer

              Source: Projections based upon IMS Market Prognosis March 2007 & Internal Analysis (excludes Japan, Australia,
                      New Zealand)
Pfizer Well-Positioned and Investing
for Growth in Emerging Asian Markets

        Asia Footprint                                                             People

   Significant 2007 Sales                                       Programs to develop and
   Growth                                                       retain talent across markets
   #1 Rank in Asia                                              Strong cadre of very
                                                                experienced managers
   Regional support footprint
   in Hong Kong with cross-                                           Three-quarters of
   functional capabilities                                            talent local

   Marketing and sales                                          Regional management team
   infrastructure in all countries                              together for nearly 10 years




  Reputation as a Good Partner, Corporate Citizen and Employer


                 Source: IMS MAT 4Q2007 (excludes Japan, Australia, New Zealand)
Capturing Global Advantage –
Building Out Today’s Presence

               R&D                                       Manufacturing
  $300 million investment in                     Manufacturing sites and experience
  South Korea                                    across Asia
  R&D facility in China                          First trigeneration power plant in
  Establish incubators to aid Asian              Singapore – an environmental-
  start-ups                                      friendly energy source
  New Asia R&D head based out of
  Shanghai and reporting to M. Mackay


                          Business Development
              Asia strategy founded on organic, internally driven growth
              Business development opportunities also exist to
              supplement growth and hedge against risk
              New head of regional and local business development
              based out of Hong Kong
Asia Strategy

                Reinforce market leadership in the region,
                grow market share from 4% to 7–9%

                     #1 pharma company in China, grow
                     market share from ~2% to ~8–11%



    Goals                Drive Korea to $1 billion business



                       Top 3 in fast-growing Asian
                       oncology market


                    Capture global advantage
     Right
   Products
                Right
              Business
               Models
   Right
Geographies
5 Key Strategies

                             Refocus
                          and Optimize
                           the Patent-
                            protected
                            Portfolio
             Instill a                     Find New
            Culture of                   Opportunities
         Innovation and                       for
           Continuous                     Established
          Improvement                      Products




                Invest in             Grow in
              Complementary          Emerging
               Businesses             Markets
       Our Path Forward
                Joe Feczko
Senior Vice President & Chief Medical Officer

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:2
posted:1/5/2012
language:English
pages:32